Fusion proteins and their applications in gene editing

By fusing T5 exonuclease into the Cas12i3 protein and designing a linker, the CRISPR/Cas12i3 gene editing system was improved, solving the problem of low editing efficiency caused by Cas12i3 protein drooping after cleavage and achieving a significant improvement in gene editing efficiency.

CN116769754BActive Publication Date: 2026-11-10CHINA AGRI UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202310509448.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-08
Publication Date
2026-11-10
Estimated Expiration
2043-05-08

AI Technical Summary

Technical Problem

The existing CRISPR/Cas12i3 gene editing system has low editing efficiency in eukaryotes, especially because the 5' overhang generated after Cas12i3 protein cleavage causes cells to be biased toward accurately repairing the break, which reduces editing efficiency.

Method used

By designing different linkers to fuse with the Cas12i3 protein to express the T5 exonuclease, the 5' overhang is removed, improving editing efficiency. The Cas12i3 protein is modified by combining C-linker 3, N-linker 4 and C-linker 1 to form fusion proteins Cas12i3-SGGSGGSGGS-T5 exo, T5 exo-XTEN-Cas12i3 and Cas12i3-(GGGGS)2-T5 exo, which enhance the editing effect.

Benefits of technology

It significantly improved the gene editing efficiency mediated by Cas12i3 protein, increasing it by 35.9% to 35.9%. Flow cytometry analysis showed an increased quenching rate of tdTomato fluorescence intensity, indicating a significant improvement in cell editing performance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004216802630000081
    Figure BDA0004216802630000081
  • Figure BDA0004216802630000091
    Figure BDA0004216802630000091
  • Figure BDA0004216802630000101
    Figure BDA0004216802630000101
Patent Text Reader

Abstract

This invention discloses fusion proteins and their applications in gene editing. Specifically, it discloses fusion proteins that improve gene editing efficiency, wherein the fusion proteins are proteins with the amino acid sequences of SEQ ID No. 9, SEQ ID No. 11, or SEQ ID No. 13. This invention also provides a gene editing system and a method for improving the efficiency of Cas12i3 protein-mediated gene editing. This invention obtained a combination of T5 exonuclease and linker-coding nucleic acid molecules that significantly improves the editing efficiency of Cas enzymes through screening. The fusion protein obtained according to this combination significantly improves the editing efficiency compared to the unmodified Cas12i3 protein. Further flow cytometry analysis showed that the C-linker 3 combination modification further significantly improved the editing efficiency of Cas enzymes. The gene editing system of this invention has high editing efficiency and has broader application value and prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of gene editing engineering and relates to fusion proteins and their applications in gene editing, specifically to nucleic acid molecule combinations encoding T5 exonuclease and linker and their applications. Background Technology

[0002] Exonucleases are a class of enzymes that catalyze the sequential hydrolysis of 3',5'-phosphodiester bonds, starting from one end of a polynucleotide chain, thus degrading nucleotides. T5 exonuclease (T5 exo) is derived from T5 bacteriophage, and this enzyme degrades double-stranded or single-stranded DNA in the 5'→3' direction.

[0003] CRISPR / Cas is an adaptive immune system developed by prokaryotes to defend against viral infections or bacteriophage invasions. Type II CRISPR / Cas9 and Type V systems (such as CRISPR / Cas12a and CRISPR / Cas12b) are simple in structure and easy to operate, and are widely used in gene editing. After recognizing a DNA target via a single guide RNA (sgRNA), the CRISPR / Cas9 system typically produces a double-strand break. The cell then repairs the double-strand break through non-homologous end joining and homologous recombination repair mechanisms, resulting in insertions, deletions, or, when a donor template is available, gene insertions and specific base changes. Currently, CRISPR / Cas9 technology is widely used in many species, including microorganisms, plants, and animals. The CRISPR / Cas system has broken through the limitations of traditional breeding and accelerated the process of genetic improvement in plants and animals.

[0004] Chinese invention patent CN111757889B discloses a Cas protein, Cas12f.4, which is referred to herein as Cas12i3. This Cas protein can be edited in eukaryotes. The cleavage sites of the Cas12i3 protein are located 15nt and 22nt downstream of PAM, producing a 7nt 5' overhang after cleavage. This overhang is complementary, causing the cell to favor the precise repair of the break during repair, thus reducing editing efficiency. Therefore, it is necessary to further improve the CRISPR / Cas12i3 gene editing system to increase its editing efficiency and develop a more efficient gene editing system, enabling it to have broader application value in gene editing, gene function research, and genetic improvement of plants and animals. Summary of the Invention

[0005] The technical problem to be solved by this invention is how to improve the efficiency of Cas12i3 protein-mediated gene editing. The technical problem to be solved is not limited to the described technical subject matter; other technical subject matter not mentioned herein will be clearly understood by those skilled in the art through the following description.

[0006] To address the aforementioned technical problems, this invention first provides a fusion protein that improves gene editing efficiency, wherein the fusion protein may be any of the following:

[0007] A1) A protein whose amino acid sequence is SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13;

[0008] A2) A protein that has more than 80% identity with and has the same function as the protein shown in A1) obtained by substituting and / or deleting and / or adding amino acid residues of the amino acid sequence shown in SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13;

[0009] A3) A fusion protein with the same function is obtained by attaching a tag or signal peptide to the N-terminus and / or C-terminus of A1) or A2).

[0010] The substitutions described herein can be conservative substitutions (also known as conservative replacements) or non-conservative substitutions in non-core functional regions. As is known to those skilled in the art, conservative substitutions or non-conservative substitutions in non-core functional regions generally do not have a qualitative impact on protein function.

[0011] The tags mentioned in this article include, but are not limited to: GST (glutathione thiotransferase) tag protein, His tag protein (His-tag), MBP (maltose-binding protein) tag protein, Flag tag protein, SUMO tag protein, HA tag protein, Myc tag protein, eGFP (enhanced green fluorescent protein), eCFP (enhanced cyan fluorescent protein), eYFP (enhanced yellow-green fluorescent protein), mCherry (monomer red fluorescent protein), or AviTag tag protein.

[0012] In this article, identity refers to the similarity of amino acid or nucleotide sequences. The identity of amino acid sequences can be determined using homology search sites on the internet, such as the BLAST page on the NCBI homepage. For example, in Advanced BLAST 2.1, using blastp as the procedure, setting the Expect value to 10, setting all filters to OFF, using BLOSUM62 as the matrix, setting the Gap existence cost, Per residue gap cost, and Lambda ratio to 11, 1, and 0.85 (default values) respectively, and performing a search to calculate the identity of amino acid sequences, then the identity value (%) can be obtained.

[0013] In this document, the 80% or more identity can be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity.

[0014] The present invention also provides a nucleic acid molecule, which may be any of the following:

[0015] B1) A nucleic acid molecule encoding any of the fusion proteins described herein;

[0016] B2) The coding sequence is a DNA molecule shown in SEQ ID No. 10, SEQ ID No. 12, or SEQ ID No. 14;

[0017] B3) The nucleotide sequence is the DNA molecule shown in SEQ ID No. 10, SEQ ID No. 12 or SEQ ID No. 14.

[0018] The nucleic acid molecule may also include nucleic acid molecules obtained by codon preference modification based on the nucleotide sequences shown in SEQ ID No. 10, SEQ ID No. 12, or SEQ ID No. 14. Considering the degeneracy of codons and the codon preferences of different species, those skilled in the art can use codons suitable for expression in specific species as needed.

[0019] The present invention also provides a biomaterial, which may be any of the following:

[0020] C1) An expression cassette containing the nucleic acid molecule;

[0021] C2) A recombinant vector containing the nucleic acid molecule or a recombinant vector containing the expression cassette described in C1);

[0022] C3) Recombinant microorganisms containing the nucleic acid molecule, or recombinant microorganisms containing the expression cassette of C1), or recombinant microorganisms containing the recombinant vector of C2);

[0023] C4) A recombinant host cell containing the nucleic acid molecule, or a recombinant host cell containing the expression cassette of C1), or a recombinant host cell containing the recombinant vector of C2).

[0024] Furthermore, the expression cassette described in C1), the recombinant vector described in C2), the recombinant microorganism described in C3), and the recombinant host cell described in C4) can all express the nucleic acid molecule.

[0025] The microorganisms described herein may be bacteria, fungi, actinomycetes, protozoa, algae, or viruses. Specifically, the bacteria may originate from genera such as *Escherichia* sp., *Erwinia* sp., *Agrobacterium* sp., and *Flavobacterium* sp., but are not limited to these. The fungi may be yeasts, and may originate from genera such as *Saccharomyces*, *Kluyveromyces*, and *Pichia pastoris*, but are not limited to these. The actinomycetes may originate from genera such as *Streptomyces* sp., *Nocardia* sp., and *Micromonospora* sp., but are not limited to these. The algae may originate from genera such as *Fucus* sp. and *Achnanthes* sp., but are not limited to these. The viruses may be rotavirus, herpesvirus, influenza virus, adenovirus, etc., but are not limited to these.

[0026] The host cell (also called the recipient cell) described herein may be a plant cell or an animal cell. The term "host cell" can be understood not only to refer to a specific recipient cell, but also to the offspring of such a cell, which may not necessarily be identical to the original parent cell due to natural, accidental, or intentional mutations and / or alterations, but are still included within the scope of the host cell. Suitable host cells are those known in the art, including: plant cells such as Arabidopsis thaliana, tobacco (Nicotiana tabacum), maize (Zea mays), rice (Oryza sativa), wheat (Triticum aestivum), etc., but not limited to these; animal cells such as mammalian cells (e.g., Chinese hamster ovary cells (CHO cells), African green monkey kidney cells (Vero cells), young hamster kidney cells (BHK cells), mouse breast cancer cells (C127 cells), human embryonic kidney cells (HEK293 cells), human HeLa cells, fibroblasts, bone marrow cell lines, T cells or NK cells, etc.), avian cells (e.g., chicken or duck cells), amphibian cells (e.g., African clawed frog (Xenopus laevis) cells or giant salamander (Andrias davidianus) cells), fish cells (e.g., grass carp, carp, rainbow trout or catfish cells), insect cells (e.g., Sf21 cells or Sf-9 cells), etc., but not limited to these. In one or more embodiments of the present invention, the host cell is a sheep fibroblast.

[0027] The present invention also provides any of the following applications of the fusion protein, the nucleic acid molecule, and / or the biomaterial:

[0028] Applications of D1 in gene editing;

[0029] Application of D2 in the preparation of gene editing systems;

[0030] Application of D3 in the preparation of gene editing products;

[0031] Application of D4 in improving gene editing efficiency.

[0032] The gene editing described herein can be gene editing targeting eukaryotes or prokaryotes, or gene editing targeting eukaryotic or prokaryotic cells. The eukaryotes may include animals or plants;

[0033] The gene-editing products described in this article may include, but are not limited to, cell models, animal or plant models, new animal or plant varieties, etc.

[0034] The present invention also provides a gene editing system, which may include at least one of the following:

[0035] E1) the fusion protein;

[0036] The nucleic acid molecule described in E2);

[0037] The recombinant vector described in E3)C2).

[0038] Furthermore, the gene editing system may also include gRNA (guide RNA) or gRNA expression vector.

[0039] The gRNA expression vector may be a recombinant vector containing a DNA molecule encoding the gRNA.

[0040] The gRNA guides the fusion protein to perform gene editing on the target gene in the target cell.

[0041] The gene editing system described in this article can be a Cas12i3 protein-mediated gene editing system (CRISPR / Cas12i3 gene editing system).

[0042] This invention also provides the application of the gene editing system in gene editing, preparation of gene editing products, or improvement of gene editing efficiency.

[0043] The present invention also provides a method for gene editing, the method comprising the steps of gene editing using the fusion protein, the nucleic acid molecule, the recombinant vector and / or the gene editing system.

[0044] Furthermore, the gene editing method may include: contacting the sample to be edited with the fusion protein, the nucleic acid molecule, the recombinant vector, and / or the gene editing system to perform gene editing.

[0045] The sample to be edited may include cells (such as animal or plant cells), tissues, organs, or combinations thereof.

[0046] The samples may be derived from animals, plants, or microorganisms (including bacteria, viruses, etc.).

[0047] The gene editing described in this article includes in vitro gene editing, in vivo gene editing, or a combination thereof.

[0048] The gene editing described in this article may include gene knockout, gene knock-in, gene mutation, gene fragment replacement, or gene modification.

[0049] The present invention also provides a method for improving the efficiency of Cas protein-mediated gene editing, the method comprising any of the following:

[0050] F1) The T5 exonuclease is linked to the C-terminus of the Cas protein via linker 3, wherein the amino acid sequence of linker 3 is SEQ ID No. 3;

[0051] F2) The T5 exonuclease is linked to the N-terminus of the Cas protein via linker 4, wherein the amino acid sequence of linker 4 is SEQ ID No. 4;

[0052] F3) The T5 exonuclease is linked to the C-terminus of the Cas protein via linker 1, the amino acid sequence of which is SEQ ID No. 1.

[0053] Furthermore, the Cas proteins may include, but are not limited to, Cas12i3, Cas9, Cas12a, Cas12b, Cas13a, and Cas14 proteins.

[0054] Furthermore, the Cas protein may be a Cas12 family protein.

[0055] Furthermore, the Cas protein may be the Cas12i3 protein.

[0056] Furthermore, the method may also include the step of constructing the nucleic acid molecule (the nucleic acid molecule encoding any of the fusion proteins described herein) and the nucleic acid molecule encoding gRNA into a vector to prepare a gene editing vector.

[0057] The fusion proteins described in this article may include Cas12i3 protein, T5 exonuclease, and linker peptide.

[0058] The amino acid sequence of the Cas12i3 protein can be positions 1-1045 of SEQ ID No. 9, and the nucleotide sequence of the gene encoding the Cas12i3 protein can be positions 1-3135 of SEQ ID No. 10.

[0059] The amino acid sequence of the T5 exonuclease can be positions 1056-1346 of SEQ ID No. 9, and the nucleotide sequence of the gene encoding the T5 exonuclease can be positions 3166-4038 of SEQ ID No. 10.

[0060] The linker may be linker 1 (amino acid sequence may be SEQ ID No. 1), linker 3 (amino acid sequence may be SEQ ID No. 3), or linker 4 (amino acid sequence may be SEQ ID No. 4).

[0061] The combination of the Cas12i3 protein, T5 exonuclease, and linker includes three modes: C-linker 3, N-linker 4, and C-linker 1. The C-linker 3 mode involves linking the T5 exonuclease to the C-terminus of the Cas12i3 protein via linker 3; the N-linker 4 mode involves linking the T5 exonuclease to the N-terminus of the Cas12i3 protein via linker 4; and the C-linker 1 mode involves linking the T5 exonuclease to the C-terminus of the Cas12i3 protein via linker 1.

[0062] In one embodiment of the present invention, the fusion protein obtained by modifying the Cas12i3 protein according to the C-linker 3 combination is Cas12i3-SGGSGGSGGS-T5 exo. The amino acid sequence of the fusion protein Cas12i3-SGGSGGSGGS-T5 exo is SEQ ID No. 9, and its encoding gene is the Cas12i3-linker 3-T5 exo gene, the nucleotide sequence of the Cas12i3-linker 3-T5 exo gene is SEQ ID No. 10.

[0063] In one embodiment of the present invention, the fusion protein obtained by modifying the Cas12i3 protein according to the N-linker 4 combination is T5 exo-XTEN-Cas12i3. The amino acid sequence of the fusion protein T5 exo-XTEN-Cas12i3 is SEQ ID No. 11, and its encoding gene is the T5 exo-linker 4-Cas12i3 gene, the nucleotide sequence of the T5 exo-linker 4-Cas12i3 gene is SEQ ID No. 12.

[0064] In one embodiment of the present invention, the fusion protein obtained by modifying the Cas12i3 protein according to the C-linker 1 combination is Cas12i3-(GGGGS)2-T5 exo. The amino acid sequence of the fusion protein Cas12i3-(GGGGS)2-T5 exo is SEQ ID No. 13, and its encoding gene is the Cas12i3-linker 1-T5 exo gene, the nucleotide sequence of the Cas12i3-linker 1-T5 exo gene is SEQ ID No. 14.

[0065] The gene editing system described herein may include a gene editing vector, which may be a recombinant vector obtained by constructing any of the nucleic acid molecules described herein and a nucleic acid molecule encoding gRNA into the vector.

[0066] In one embodiment of the present invention, the gRNA is a gRNA targeting the sheep endogenous gene ZFX, and the target sequence of the gRNA is SEQ ID No. 15. The gene editing vector comprises: a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 15 and the Cas12i3-linker 3-T5 exo gene (SEQ ID No. 10) into a vector; a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 15 and the T5 exo-linker 4-Cas12i3 gene (SEQ ID No. 12) into a vector; and a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 15 and the Cas12i3-linker 1-T5 exo gene (SEQ ID No. 14) into a vector.

[0067] The gene editing vector described above contains the ZFX gene editing target and the fusion gene designed in this invention (including the gene encoding the Cas12i3 protein, the gene encoding the T5 exonuclease, and the linker gene designed in this invention). After being introduced into recipient cells, the guide RNA transcribed from it can target the ZFX gene through base complementarity pairing. The fusion protein expressed by it (the fusion protein formed by the connection of the Cas12i3 protein and the T5 exonuclease through the linker) causes DNA double-strand breaks upstream and downstream of the ZFX gene target. Through the organism's own DNA damage repair response mechanism, the gene editing function is further realized.

[0068] In another embodiment of the present invention, the gRNA is a gRNA targeting the tdTomato gene, and the target sequence of the gRNA is SEQ ID No. 16. The gene editing vector comprises: a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 16 and the Cas12i3-linker 3-T5 exo gene (SEQ ID No. 10) into a vector; a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 16 and the T5 exo-linker 4-Cas12i3 gene (SEQ ID No. 12) into a vector; and a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 16 and the Cas12i3-linker 1-T5 exo gene (SEQ ID No. 14) into a vector.

[0069] The gene editing vector described above contains the tdTomato gene editing target and the fusion gene designed in this invention (including the gene encoding the Cas12i3 protein, the gene encoding the T5 exonuclease, and the linker gene designed in this invention). After being introduced into recipient cells, the guide RNA transcribed from it can target the tdTomato gene through base complementarity pairing. The fusion protein expressed by it (the fusion protein formed by the connection of the Cas12i3 protein and the T5 exonuclease through the linker) causes DNA double-strand breaks upstream and downstream of the tdTomato gene target. Through the organism's own DNA damage repair response mechanism, the gene editing function is further realized.

[0070] Chinese invention patent CN111757889B discloses a Cas protein, Cas12f.4, which is referred to herein as Cas12i3. This Cas protein can be edited in eukaryotes. The Cas12i3 protein cleavage site is located 15nt and 22nt downstream of PAM, producing a 7nt 5' overhang after cleavage. The complementary pairing of these overhangs leads to a bias in the precise repair of the break during cell repair, reducing editing efficiency. This invention designs different linkers to fuse T5 exonuclease with the Cas12i3 protein for expression, thereby cleaving the 5' overhang and improving the editing efficiency of Cas12i3, laying the foundation for the widespread application of the CRISPR / Cas12i3 gene editing system.

[0071] This invention screened and obtained T5 exonuclease and linker-coding sequence nucleic acid molecule combinations (C-linker 3 combination, N-linker 4 combination, and C-linker 1 combination) that can significantly improve the editing efficiency of Cas enzyme. The fusion proteins obtained by the C-linker 3, N-linker 4, and C-linker 1 combinations showed significantly improved editing efficiency compared to the unmodified Cas12i3 protein, with increases of 35.9%, 32.5%, and 35.9%, respectively. Further flow cytometry analysis of the editing efficiency of different combinations showed that the C-linker 3 combination improved the quenching ratio of the average tdTomato fluorescence intensity and significantly increased the fluorescence intensity of weak tdTomato (<10). 3 The percentage of cells showing a shift in the overall tdTomato fluorescence peak (the coordinate axis from left to right represents the fluorescence intensity of tdTomato from weak to strong) indicates that the C-linker 3 combination modification significantly improves the editing efficiency of the Cas enzyme. The gene editing system prepared using the fusion protein of this invention exhibits good gene editing efficiency and has good application value and prospects. Attached Figure Description

[0072] Figure 1 To determine the editing efficiency of eight different nucleic acid molecule combinations in sheep fibroblasts for T7E1 (48 h post-transfection).

[0073] Figure 2 To analyze the proportion of tdTomato-labeled sheep fibroblasts quenched by eight different combinations of nucleic acid molecules (48 h post-transfection).

[0074] Figure 3 To analyze the weak tdTomato fluorescence intensity (<10) in sheep fibroblasts labeled with tdTomato caused by eight different combinations of nucleic acid molecules, flow cytometry was used. 3Changes in the proportion of cells (48 h post-transfection).

[0075] Figure 4 The tdTomato fluorescence distribution peaks of sheep fibroblasts transfected with the control group plasmid and the plasmid containing the T5 exonuclease fused to the C-terminus of Cas12i3 via linker 3 (C-linker3 combination) are shown (48 h post-transfection). Detailed Implementation

[0076] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.

[0077] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following examples are commercially available.

[0078] definition

[0079] While the following terms are believed to be obvious to those skilled in the art, the following definitions are set forth in order to explain the subject matter disclosed in this application.

[0080] gRNA

[0081] "Guide RNA" and "mature crRNA" are used interchangeably and have the meanings commonly understood by those skilled in the art. Generally, guide RNA may comprise a direct repeat sequence and a guide sequence, or essentially consist of a direct repeat sequence and a guide sequence (also called a spacer sequence in the context of an endogenous CRISPR system). In some cases, the guide sequence is any polynucleotide sequence that is sufficiently complementary to the target sequence to hybridize with it and guide the specific binding of the CRISPR / Cas complex to the target sequence.

[0082] Cas protein

[0083] In this invention, the term "Cas protein" refers to a CRISPR protein, and the terms "CRISPR / Cas protein," "Cas effector protein," "Cas protein," and "single-effect nuclease" are used interchangeably. A ribonucleoprotein complex formed by the Cas protein and gRNA or mature crRNA once bound to a target sequence contains a guide sequence that hybridizes to the target sequence and binds to the Cas protein. This ribonucleoprotein complex can recognize and cleave polynucleotides that hybridize with the guide RNA or mature crRNA.

[0084] T5 exonuclease

[0085] T5 exonucleases are a class of enzymes that catalyze the sequential hydrolysis of 3,5-phosphodiester bonds, starting from one end of a polynucleotide chain, thus degrading nucleotides. T5 exonucleases originate from T5 bacteriophages and degrade double-stranded or single-stranded DNA in a 5'→3' direction.

[0086] Fusion protein

[0087] Fusion proteins are proteins created by linking two proteins or polypeptides together with peptide bonds. The concept of fusion proteins has important applications in cell biology research and macromolecular drug development. The principle of constructing fusion proteins is to delete the stop codon of the first protein gene and then add a second protein gene containing the stop codon, thus achieving the fusion expression of the two genes. Common fusion proteins include target protein fusion tag proteins, fusion fluorescent proteins, and the fusion of two different proteins.

[0088] linker

[0089] Also known as "linker peptides" or "connectors," linkers are an indispensable component of recombinant fusion proteins, playing a crucial role in constructing stable and biologically active fusion proteins. A linker is an amino acid chain that connects two fusion proteins, possessing a degree of flexibility to allow the proteins on either side to perform their respective independent functions. Direct fusion of functional regions without a linker can lead to many undesirable results, including misfolding of the fusion protein, low protein yield, or impaired biological activity. Therefore, selecting or rationally designing linkers that connect the domains of fusion proteins is an important area in recombinant fusion protein technology.

[0090] Several factors should be considered when designing a linker: 1) Linker length. It should not be too long or too short, generally between 10 and 15 amino acids. An excessively long linker sequence may reduce fusion protein yield and cause immunogenicity problems; an excessively short linker sequence may cause the two proteins to be too close together, affecting the folding of their higher-order structures, thus interfering with each other and leading to loss of protein function. 2) Linker structure. When designing the linker sequence, care should be taken to avoid the generation of secondary structures, as these can restrict the stretchability of the fusion protein, thereby affecting its functional activity. 3) Common amino acids in the linker. Nonpolar hydrophobic amino acids such as glycine (Gly), serine (Ser), and proline (Pro) are commonly found. 4) Nucleotide sequence within the linker. Studies have shown that adjusting the nucleotide composition of the linker sequence can significantly increase the mRNA level of the recombinant fusion protein and improve transfection efficiency.

[0091] nuclear localization signal

[0092] A nuclear localization signal (NLS) is an amino acid sequence that "tags" a protein to allow it to be transported to the nucleus via nuclear transport; that is, a protein with an NLS is transported to the nucleus. Typically, an NLS contains positively charged Lys or Arg residues exposed on the protein surface. Exemplary nuclear localization sequences include, but are not limited to, NLS from the following: SV40 large T antigen, EGL-13, c-Myc, and TUS protein. In some embodiments, the NLS contains the PAAKRVKLD sequence (c-Myc NLS). In some embodiments, the NLS contains the KRTADGSEFESPKKKRKV sequence (BP NLS). In some embodiments, the NLS contains the KRPAATKKAGQAKKKK sequence (nucleoplasmin NLS).

[0093] c-Myc NLS nucleotide sequence CCCGCCGCCAAGCGCGTGAAGCTGGAC,

[0094] c-Myc NLS amino acid sequence PAAKRVKLD,

[0095] BP NLS nucleotide sequence AAACGGACAGCCGACGGAAGCGAGTTCGAGTCACCAAAGAAGAAGCGGAAGGTC,

[0096] BP NLS amino acid sequence KRTADGSEFESPKKKRKV,

[0097] nucleoplasmin NLS nucleotide sequence: AAGAGGCCTGCTGCTACAAAGAAGGCCGGCCAGGCAAAAAAGAAAAAG

[0098] nucleoplasmin NLS amino acid sequence KRPAATKKAGQAKKKK.

[0099] carrier

[0100] A recombinant DNA vector is a self-replicating DNA molecule used in genetic engineering to transfer DNA fragments (target genes) into recipient cells. The three most commonly used vectors are bacterial plasmids, bacteriophages, and plant and animal viruses. Vectors can be classified into cloning vectors and expression vectors according to their function. Cloning vectors are the simplest vectors and are mainly used to clone and amplify DNA fragments. They mainly include plasmid vectors, bacteriophage vectors, and viral vectors. Expression vectors, in addition to the basic elements of cloning vectors, also contain DNA elements necessary for transcription and translation, such as promoters and terminators. The promoters discussed in this article are the U6 and CBh promoters. The U6 promoter belongs to the pol III type promoter, and the sequence it drives is very short. Currently, common expression vectors using the U6 promoter include gRNA and siRNA. The sequence driven by the U6 promoter terminates upon encountering pol(U). The CBh promoter is an artificially constructed combinatorial promoter composed of a mixed sequence of the cytomegalovirus (CMV), early enhancer, chicken beta-actin promoter, and chicken beta-actin (CBA) and mouse minute virus (MMV) introns, used to drive high-level gene expression in mammalian vectors.

[0101] T7E1 enzyme digestion

[0102] T7E1, short for T7 Endonuclease I, is a unique DNA endonuclease that can recognize and cleave incompletely paired DNA, cross-shaped DNA structures, Holliday structures, and other DNA editing techniques. T7E1 is commonly used for detecting mutants created by CRISPR / Cas, TALEN, and other editing tools.

[0103] The primary goat or sheep fibroblasts used in the following examples were isolated in the laboratory. The preparation method is as follows: A small amount of ear tissue from a goat or sheep within 2 weeks of birth was taken and placed in PBS. In a laminar flow hood, the ear tissue was sterilized in 75% alcohol for 1 minute, washed 3 times with PBS, and then minced to 1 mm using sterile scissors. 3 Add 200 μL of fetal bovine serum to the culture dish and incubate upside down at 37°C with 5% CO2 for 1 hour. Carefully add complete culture medium, being careful not to dislodge the tissue block during addition. After about one week of culture, fibroblasts will emerge from the tissue block. Once the cell line has reached confluence, trypsinize the cells, expand the culture, and then freeze for later use.

[0104] In the following examples, the amino acid sequence of the Cas12i3 protein is positions 1-1045 of SEQ ID No. 9, and the nucleotide sequence of the gene encoding the Cas12i3 protein is positions 1-3135 of SEQ ID No. 10.

[0105] In the examples below, the amino acid sequence of T5 exonuclease (abbreviated as T5 exo) is positions 1056-1346 of SEQ ID No. 9, and the nucleotide sequence of the encoding gene of T5 exonuclease is positions 3166-4038 of SEQ ID No. 10.

[0106] The PX458 vector in the following examples is derived from the Addgene plasmid sharing information database (number 48138).

[0107] In the following examples, the amino acid sequence of linker 1 is SEQ ID No. 1, and the nucleotide sequence is SEQ ID No. 5; the amino acid sequence of linker 2 is SEQ ID No. 2, and the nucleotide sequence is SEQ ID No. 6; the amino acid sequence of linker 3 is SEQ ID No. 3, and the nucleotide sequence is SEQ ID No. 7; and the amino acid sequence of linker 4 is SEQ ID No. 4, and the nucleotide sequence is SEQ ID No. 8.

[0108] Example 1: Designing different combinations of T5 exonucleases and linkers for nucleic acid molecules.

[0109] This embodiment designed different combinations of T5 exonuclease and linker nucleic acid molecules to construct fusion genes. Considering the size of the Cas12i3 protein and the T5 exonuclease, the selected linker was 8-16 amino acids long. Four linkers were designed: (GGGGS)2, (GGGGS)3, SGGSGGSGGS, and XTEN, and renamed linker 1, linker 2, linker 3, and linker 4, respectively. The T5 exonuclease was fused to the N-terminus or C-terminus of the Cas12i3 protein through these four linkers, resulting in a total of eight nucleic acid molecule combinations and eight fusion genes. The coding genes for the Cas12i3 protein, the T5 exonuclease, and the four linkers were all optimized with mammalian codons. To enhance the nuclear translocation capability of the fusion protein, nuclear localization signal (NLS) sequences were added to the N-terminus and C-terminus of the eight fusion genes in this embodiment. Add c-Myc NLS and BP NLS coding sequences to the N-terminus, and add nucleoplasmin NLS coding sequences to the C-terminus.

[0110] Eight recombinant vectors were constructed based on the above approach, as shown in Table 1:

[0111] Table 1. Construction of 8 nucleic acid molecule combinations and vectors

[0112]

[0113]

[0114] The construction methods for the above eight recombinant vectors are as follows:

[0115] 1. Synthesize 8 fusion genes

[0116] The eight fusion genes are fusion genes formed by directly linking the gene encoding the Cas12i3 protein (SEQ ID No. 10, positions 1-3135) and the gene encoding the T5 exonuclease (T5 exo) (SEQ ID No. 10, positions 3166-4038) through the gene encoding linker 1 (SEQ ID No. 5), the gene encoding linker 2 (SEQ ID No. 6), the gene encoding linker 3 (SEQ ID No. 7), or the gene encoding linker 4 (SEQ ID No. 8) in eight different combinations (Table 1).

[0117] The fusion genes synthesized according to the combinations of N-linker 1 to N-linker 4 were named T5 exo-linker1-Cas12i3, T5 exo-linker 2-Cas12i3, T5 exo-linker 3-Cas12i3, and T5 exo-linker4-Cas12i3, respectively; the fusion genes synthesized according to the combinations of C-linker 1 to C-linker 4 were named Cas12i3-linker 1-T5 exo, Cas12i3-linker 2-T5 exo, Cas12i3-linker 3-T5 exo, and Cas12i3-linker 4-T5 exo, respectively.

[0118] 2. Construction of 8 recombinant vectors

[0119] PX458 (U6-sgRNA-CBh-Cas9-T2A-EGFP-bGH polyA) was double-digested with restriction endonucleases BbsI (NEB (Beijing) Co., Ltd.) and XbaI (NEB (Beijing) Co., Ltd.) to remove the sgRNA scaffold sequence. The digestion system consisted of 5 μg PX458, 25 units of BbsI, 25 units of XbaI, 10 μL of Cutsmart, and ddH2O to a final volume of 100 μL. The reaction conditions were: incubation at 37°C for 6 h. The DNA was recovered and its concentration determined using a recovery kit (Guangzhou Meiji Biotechnology Co., Ltd., catalog number D2111-02). Primers 5'-CACCACTAGTT-3' and 5'-CTAGAACTAGT-3' were synthesized and annealed to generate a DNA double strand complementary to the digested linear PX458 vector. Annealing system: 2.5 μL of 5'-CACCACTAGTT-3' (100 μM), 2.5 μL of 5'-CTAGAACTAGT-3' (100 μM), 1 μL of T4 ligase buffer, and ddH2O to a final volume of 10 μL. Annealing procedure: 95℃ for 5 min in a metal bath, then open the metal bath lid, close the metal bath, and allow to cool to room temperature. The recovered linear PX458 vector (double-digested with BbsI and XbaI) was ligated with the annealing product using a T4 ligase kit (Baori Biotechnology Co., Ltd.) to form U6-CBh-Cas9-T2A-EGFP-bGHpolyA.

[0120] The plasmid U6-CBh-Cas9-T2A-EGFP-bGH polyA was digested with the restriction endonucleases AgeI (NEB (Beijing) Co., Ltd.) and FseI (NEB (Beijing) Co., Ltd.) to remove the Cas9 coding sequence. The digestion system consisted of 5 μg of the plasmid (U6-CBh-Cas9-T2A-EGFP-bGH polyA), 20 units of AgeI, 20 units of FseI, 10 μL of cutsmart, and ddH2O to a final volume of 100 μL. The reaction was carried out at 37°C for 6 h. The plasmid was recovered and its concentration was determined using a recovery kit (Guangzhou Meiji Biotechnology Co., Ltd., catalog number D2111-02). The enzyme digestion products (AgeI and FseI double-digested plasmid U6-CBh-Cas9-T2A-EGFP-bGH polyA), the coding sequence of Cas12i3 protein (serial positions 1-3135 of SEQ ID No. 10), c-Myc NLS, BPNLS, and nucleoplasmin NLS were assembled using a seamless cloning kit to obtain U6-CBh-c-Myc NLS-BP NLS-Cas12i3-nucleoplasmin NLS-T2A-EGFP-bGH polyA, which was used as a control vector.Simultaneously, the enzyme digestion products (AgeI and FseI double-digested plasmid U6-CBh-Cas9-T2A-EGFP-bGH polyA), the Cas12i3 protein coding sequence, the T5 exo coding sequence, the linker (linker 1, linker 2, linker 3, or linker 4), c-Myc NLS, BP NLS, and nucleoplasmin NLS were assembled using a seamless cloning kit according to the combinations shown in Table 1 to obtain the recombinant vectors U6-CBh-c-Myc NLS-BP NLS-T5 exo-linker1-Cas12i3-nucleoplasmin NLS-T2A-EGFP-bGH polyA, U6-CBh-c-Myc NLS-BP NLS-T5exo-linker 2-Cas12i3-nucleoplasmin NLS-T2A-EGFP-bGH polyA, and U6-CBh-c-Myc NLS-BP NLS-T5 exo-linker 3-Cas12i3-nucleoplasminNLS-T2A-EGFP-bGH polyA, U6-CBh-c-Myc NLS-BP NLS-T5 exo-linker 4-Cas12i3-nucleoplasmin NLS-T2A-EGFP-bGH polyA, U6-CBh-c-Myc NLS-BP NLS-Cas12i3-linker1-T5 exo-nucleoplasmin NLS-T2A-EGFP-bGH polyA, U6-CBh-c-Myc NLS-BP NLS-Cas12i3-linker 2-T5 exo-nucleoplasmin NLS-T2A-EGFP-bGH polyA, U6-CBh-c-MycNLS-BP NLS-Cas12i3-linker 3-T5exo-nucleoplasmin NLS-T2A-EGFP-bGH polyA and U6-CBh-c-Myc NLS-BP NLS-Cas12i3-linker 4-T5 exo-nucleoplasmin NLS-T2A-EGFP-bGHpolyA.

[0121] The above 8 recombinant vectors express 8 fusion proteins (i.e., fusion proteins encoded by 8 fusion genes), which are named as follows: T5 exo-(GGGGS)2-Cas12i3, T5 exo-(GGGGS)3-Cas12i3, T5exo-SGGSGGSGGS-Cas12i3, T5exo-XTEN-Cas12i3, Cas12i3-(GGGGS)2-T5 exo, Cas12i3-(GGGGS)3-T5 exo, Cas12i3-SGGSGGSGGS-T5 exo, and Cas12i3-XTEN-T5 exo.

[0122] Example 2: T7E1 restriction enzyme digestion method to detect the editing efficiency of nucleic acid molecules combined with different T5 exonucleases and linkers.

[0123] 1. Construction of gene editing vectors

[0124] The eight recombinant vectors and control vectors constructed in Example 1 were digested and recovered using double enzyme digestion with KpnI (NEB (Beijing) Co., Ltd.) and SpeI (NEB (Beijing) Co., Ltd.) (the U6 promoter has SpeI and KpnI restriction sites). The digestion system consisted of 5 μg of the plasmid, 50 units of SpeI, 50 units of KpnI, 10 μL of cutsmart, and ddH2O to a final volume of 100 μL. The reaction conditions were: incubation at 37°C for 6 h. Then, 5 μL of BeyoAP alkaline phosphatase (Beyotime Biotechnology Co., Ltd., catalog number D7027) was added, and incubation continued at 37°C for 10 min. The recombinant vectors were recovered and their concentrations determined using a recovery kit (Guangzhou Meiji Biotechnology Co., Ltd., catalog number D2111-02).

[0125] This invention selects the sheep endogenous gene ZFX (GenBank Accession No. NC_056080.1, positions 22500545-22537460 (Update Date 4-Nov-2022)) and designs a target sequence for the gRNA (gRNA1) targeting the ZFX gene. The target sequence is 5'-CAGTACAGCAAGAGTGGATGAAT-3' (SEQ ID No. 15). The DNA fragment expressing the gRNA (5'-aaaggacgaaacaccGCTCTGACCACCTGAGAGAATGTGTGCATAGTCACACCAGTACAGC AAGAGTGGATGAATTTTTTTTgtacccgttacataa-3') is amplified using the primers listed below (Table 2), where uppercase letters indicate direct repeat sequences + target sequences + transcription termination signals, and lowercase letters indicate vector homologous sequences. PCR amplification system: F 1 μL, R 1 μL, PrimeSTAR 15 μL, ddH2O 13 μL. PCR amplification program: 98℃ pre-denaturation for 3 min; 98℃ denaturation for 10 s, 60℃ annealing for 15 s, 72℃ extension for 5 s (33 cycles); 72℃ extension for 5 min. After PCR, the PCR product was recovered and its concentration determined using a product recovery kit (Guangzhou Meiji Biotechnology Co., Ltd., catalog number D2111-02).

[0126] Table 2. Primers used to amplify DNA fragments expressing gRNA (targeting the ZFX gene)

[0127]

[0128] Using a seamless cloning kit, the above gRNA fragments were homologously recombined with linear control vectors digested with SpeI and KpnI and eight recombinant vectors to form control vectors with the ZFX target and eight recombinant vectors, which are the gene editing vectors.

[0129] The eight gene editing vectors constructed above were named pCBh-N-linker 1-gRNA1, pCBh-N-linker 2-gRNA1, pCBh-N-linker 3-gRNA1, pCBh-N-linker 4-gRNA1, pCBh-C-linker 1-gRNA1, pCBh-C-linker 2-gRNA1, pCBh-C-linker 3-gRNA1, and pCBh-C-linker 4-gRNA1, respectively.

[0130] The gene editing vector described above contains the ZFX gene editing target and the fusion gene designed in this invention (including the gene encoding the Cas12i3 protein, the gene encoding the T5 exonuclease, and the linker gene designed in this invention). After being introduced into recipient cells, the guide RNA transcribed from it can target the ZFX gene through base complementarity pairing. The fusion protein expressed by it (the fusion protein formed by the connection of the Cas12i3 protein and the T5 exonuclease through the linker) causes DNA double-strand breaks upstream and downstream of the ZFX gene target. After the breaks, T5 exo can remove the protruding overhang, thereby preventing the cell from accurately repairing the DNA, increasing the insertion / deletion ratio, and further realizing the gene editing function.

[0131] 2. Cell electroporation

[0132] Primary sheep fibroblasts in good condition were transferred to 10 cm culture dishes and cultured until the cell confluence reached approximately 80%. Cells were collected by trypsin digestion into EP tubes. The cells were resuspended in 100 μL of electroporation buffer (Beijing Enggen Biotechnology Co., Ltd., catalog number 98668-20) and 7 μg of plasmid (gene editing vector) was added and mixed thoroughly. The cells were then placed in a Lonza Amaxa Nucleofector 2B transfection instrument, programmed A-033, and electroporated. Immediately after electroporation, 500 μL of DMEM high-glucose medium was added, and the cells were incubated at 37°C for 10 min. Cells were then seeded into 6-well plates with complete medium containing 20% ​​FBS. After 6 h, the medium was replaced with complete medium containing 15% FBS.

[0133] 3. T7E1 tests editing efficiency

[0134] Cells electroporated for 48 hours had their genome extracted using a genome extraction kit (Guangzhou Meiji Biotechnology Co., Ltd., catalog number D3018-02). 100 ng of the extracted sheep genome was used as a template for PCR amplification. The amplification reaction system and program were as follows: The total volume of the amplification reaction was 50 μL. Primers listed in Table 3 were used for amplification, with the following components: 100 ng DNA template, 1 μL each of 10 μmol / L primers, 25 μL PrimeSTAR (Baori Biotechnology Co., Ltd.), and the volume was brought to 50 μL with sterile deionized water. The PCR reaction program was: 98℃ pre-denaturation for 3 min; 98℃ denaturation for 10 s, 60℃ annealing for 15 s, 72℃ extension for 30 s (33 cycles); and a final extension at 72℃ for 5 min. After PCR, the PCR products were recovered using a product recovery kit, and their concentration was determined.

[0135] Table 3. Primers for obtaining sequences around the target site

[0136]

[0137] Take the PCR product recovered in the previous step and prepare the enzyme digestion system as follows: 500 ng of amplified product, 1.1 μL of Cutsmart, and ddH2O to a final volume of 11.5 μL. After mixing thoroughly, follow the hybridization program: 95℃ for 10 min; -2℃ / s to 85℃; -0.1℃ / s to 25℃. Add 0.5 μL of T7E1 (NEB (Beijing) Co., Ltd.), digest at 37℃ for 15 min, immediately add 2 μL of Loading Buffer, prepare 2% agarose gel for electrophoresis analysis, and observe and analyze the results after enzyme digestion using a gel imaging system.

[0138] Image obtained by agarose gel electrophoresis ( Figure 1 The editing efficiency of the fusion protein T5 exo-XTEN-Cas12i3 (N-linker4 combination, amino acid sequence SEQ ID No. 11) was observed to be 15.5%, which was 32.5% higher than that of the unmodified Cas12i3 protein; the editing efficiency of the fusion protein Cas12i3-(GGGGS)2-T5 exo (C-linker 1 combination, amino acid sequence SEQ ID No. 13) was 15.9%, which was 35.9% higher than that of the unmodified Cas12i3 protein; the editing efficiency of the fusion protein Cas12i3-SGGSGGSGGS-T5 exo (C-linker 3 combination, amino acid sequence SEQ ID No. 9) was 15.9%, which was 35.9% higher than that of the unmodified Cas12i3 protein. Compared with the control group (unmodified Cas12i3 protein) of 11.7%, the editing efficiency was significantly improved.

[0139] Example 3: Flow cytometry analysis to detect the editing efficiency of nucleic acid molecules combined with different T5 exonucleases and linkers.

[0140] 1. Construction of sheep fibroblasts labeled with tdTomato red fluorescent dye

[0141] 1-1. Construction of CRISPR / Cas9 gene targeting vector

[0142] 1-1-1. Enzyme digestion of PX458 vector

[0143] Enzyme digestion system: 5 μg PX458 vector, 50 units of BbsI, 10 μL Cutsmart, and ddH2O to a final volume of 100 μL. Digestion was performed at 37℃ for 5 h. After digestion, the digestion product was purified using a product purification kit (Guangzhou Meiji Biotechnology Co., Ltd.) to obtain purified PX458 BbsI digestion product. An oligo was designed targeting the goat ZFY gene sequence, and the target sequence was synthesized according to Table 4.

[0144] Table 4. sgRNA target sequences

[0145]

[0146] 1-1-2, Oligo annealing

[0147] The designed oligo was annealed according to the following annealing system and procedure to form an annealed product (double-stranded DNA).

[0148] Annealing system: ZFY-sgRNA-F (100μM) 2.5μL, ZFY-sgRNA-R (100μM) 2.5μL, T4 ligase buffer 1μL, ddH2O to a final volume of 10μL. Annealing procedure: 95℃ for 5 min in a metal bath, then turn off the metal bath, open the lid, and allow it to cool to room temperature before removing it.

[0149] 1-1-3, Connection

[0150] The annealing product was diluted 50 times and ligated with the PX458BbsI digestion product in step 1-1-1 according to the following ligation system and procedure.

[0151] Ligation system: 90 ng PX458 BBSI digestion product, 1 μL annealing product (diluted), 0.5 μL T4 ligase, 1 μL T4 ligase buffer, and ddH2O to a final volume of 10 μL. Ligation procedure: 25℃ for 1 h.

[0152] 10 μL of the above ligation product was used for transformation, bacteria were selected, sequencing was performed, and plasmid was extracted to construct a CRISPR / Cas9 gene targeting vector (i.e., sgRNA expression vector), named PX458-ZFY-sgRNA.

[0153] 1-2. Constructing donor plasmids

[0154] Our laboratory has stored the pCBh-tdTomato-SV40 polyA plasmid. The construction process of this plasmid is as follows: First, pROSA26-promoter (Addgene 21710) is digested with SpeI and XbaI to obtain the digested pROSA26-promoter. The DNA molecule shown in SEQ ID No. 17 (tdTomato-SV40 polyA sequence) is ligated to the digested pROSA26-promoter using seamless cloning assembly technology to obtain pROSA26-tdTomato-SV40 polyA. The CBh promoter was obtained by double digestion of px458 with KpnI and AgeI. Using pROSA26-tdTomato-SV40 polyA as a template, the sequence other than the ROSA26 promoter was amplified with primer F (5'-tttttttcaggttggaccggTGCCACCATGGACTAGTATGGTGAGCAAGGGCGA-3') and primer R (5'-taccgtaagttatgtaacggggtacCCAGCTTTTGTTCCCTTTAGT-3'). This sequence was then combined with the CBh promoter sequence using seamless cloning assembly technology to construct pCBh-tdTomato-SV40 polyA.

[0155] This plasmid was able to express red fluorescence normally in primary goat fibroblasts. The sequences flanking the site of cleavage by the nuclease at the ZFY target site (3-4 bp upstream of PAM) were used as homologous arms (left homologous arm (HA-L) 925 bp, nucleotide sequence SEQ ID No. 18; right homologous arm (HA-R) 958 bp, nucleotide sequence SEQ ID No. 19). The left and right homologous arms were amplified by PCR using the primers in Table 5, and the products were recovered using a PCR product recovery kit (Meiji Biotechnology Co., Ltd.).

[0156] The plasmid pCBh-tdTomato-SV40 polyA was digested with enzymes. Using seamless cloning assembly technology, the left and right homologous arms of the ZFY target were cloned to both ends of pCBh-tdTomato-SV40 polyA, constructing the plasmid HA-L-CBh-tdTomato-SV40polyA-HA-R. Subsequently, the ZFY target recognition sequence was added to the outer sides of the left and right homologous arms to construct the donor plasmid type required for HMEJ (homology-mediated end joining). Furthermore, although the left and right homologous arms of the constructed donor plasmid were derived from goats, they showed extremely high homology with their sheep counterparts. NCBIBLAST comparison showed that the homology of the left homologous arm was 96.11%, and the homology of the right homologous arm was 97.66%. The nucleotide sequence of the sheep left homologous arm is SEQ ID No. 20, and the nucleotide sequence of the sheep right homologous arm is SEQ ID No. 21.

[0157] Table 5. Primers for the left and right homologous arms of ZFY

[0158]

[0159] 1-3. Construction of sheep fibroblasts labeled with tdTomato red fluorescent dye.

[0160] Using the CRISPR / Cas9 gene targeting vector PX458-ZFY-sgRNA and donor plasmid HA-L-CBh-tdTomato-SV40polyA-HA-R (carrying the exogenous tdTomato gene; although its homologous arm originates from goats, it has high homology with the corresponding homologous arm in sheep, and is therefore expected to be used in sheep) constructed in this embodiment, the exogenous gene (tdTomato gene) was site-directedly integrated into the ZFY gene targeting site via HMEJ-mediated recombination, thus constructing a sheep fibroblast cell line with site-directed integration of the exogenous gene into the ZFY gene. The specific steps are as follows:

[0161] 1-3-1. Co-transfection of sheep fibroblasts with gene-editing plasmid and donor plasmid

[0162] 5000 ng of the constructed donor plasmid HA-L-CBh-tdTomato-SV40 polyA-HA-R and 9536 ng of the gene targeting vector PX458 (PX458-ZFY-sgRNA) carrying the ZFY target (molar ratio 1:1.5) were electroporated into primary sheep fibroblasts (the electroporation procedure was the same as step 2 in Example 2, only the plasmids were different). After 24 hours, tdTomato and EGFP-positive primary sheep fibroblasts were sorted by flow cytometry and seeded at approximately 500 cells per 10 cm cell culture dish. After 2 weeks of culture, the cells in the cell culture dish were individually digested into 96-well plates using a cloning loop.

[0163] 1-3-2. Screening of sheep fibroblasts by site-specific integration of tdTomato

[0164] After the cell clones in the 96-well plate have grown to confluence, digest the cells, leaving half of the wells for initial culture, and transfer the other half of the cells to 1.5 mL centrifuge tubes. Centrifuge at 12000 rpm for 3 min, discard the supernatant, and add 50 μL of cell identification lysis buffer (prepared as follows: 2 mL Tris-HCl (1 M, pH 8.0), 0.45 mL Triton X-100, 0.45 mL NP-40, 0.02 g proteinase K, dissolved in deionized water and brought to a final volume of 50 mL, filtered through a 0.22 μm filter). Thoroughly resuspend the cells and lyse them according to the following program: 65 °C, 30 min; 95 °C, 15 min; 16 °C, infinity. Use the resulting lysate as a DNA template.

[0165] Design primers according to Table 6 and perform PCR identification.

[0166] Table 6. Primers for site-specific integration identification

[0167]

[0168] Amplification reaction system and procedure: The total volume of the amplification reaction was 50 μL, with the following components: 1 μL DNA template, 1 μL each of 10 μmol / L primers, 10 μL PrimeSTAR (Baori Biotechnology Co., Ltd.), and the volume was brought up to 20 μL with sterile deionized water. The PCR reaction procedure was as follows: 98℃ pre-denaturation for 3 min; 98℃ denaturation for 10 s, 62℃ annealing for 15 s, 72℃ extension for 50 s (33 cycles); and a final extension at 72℃ for 5 min. The results were detected by agarose gel electrophoresis after PCR.

[0169] The results showed that 16 cell clones were lysed, and 3 clones were identified by PCR as ZFY-integrated single-cell clones. Simultaneously, fluorescence microscopy revealed that all three clones emitted red fluorescence. This indicates that the exogenous gene (tdTomato gene) underwent site-specific integration at the target site, successfully constructing tdTomato-labeled sheep fibroblasts.

[0170] 2. Design target sequences and construct gene editing vectors

[0171] In this embodiment, the ZFY-integrated tdTomato cell clone constructed in step 1 above was selected as the cell line for subsequent evaluation of the editing efficiency of linking T5 and Cas12i3 through different linkers. In this embodiment, a gRNA (gRNA2) targeting tdTomato was designed based on the tdTomato coding sequence (positions 2529-3959 of GenBank Accession No. KT878736.1 (Update Date 06-OCT-2015)), with the target sequence being 5'-AAGACCATCTACATGGCCAAGAA-3' (SEQ ID No. 16). The DNA fragment expressing the gRNA sequence (5'-aaaggacgaaacaccGCTCTGACCACCTGAGAGAATGTGTGCATAGTCACACAAGACCATCT ACATGGCCAAGAATTTTTTTgtacccgttacataa-3', where uppercase letters indicate direct repeat sequences, target sequences, and transcription termination signals, and lowercase letters indicate vector homologous sequences) was amplified using the primers in Table 7. The PCR product was then recovered using a product recovery kit (Guangzhou Meiji Biotechnology Co., Ltd., catalog number D2111-02) and its concentration was determined.

[0172] Table 7 Primers used to amplify DNA fragments expressing gRNA (targeting the tdTomato gene)

[0173]

[0174] Using a seamless cloning kit, the above gRNA fragments were homologously recombined with the linear control vector and eight recombinant vectors digested with SpeI and KpnI in Example 2 to form a control vector with the tdTomato target and eight recombinant vectors, which are the gene editing vectors.

[0175] The eight gene editing vectors constructed above were named pCBh-N-linker 1-gRNA2, pCBh-N-linker 2-gRNA2, pCBh-N-linker 3-gRNA2, pCBh-N-linker 4-gRNA2, pCBh-C-linker 1-gRNA2, pCBh-C-linker 2-gRNA2, pCBh-C-linker 3-gRNA2, and pCBh-C-linker 4-gRNA2, respectively.

[0176] The gene editing vector described above contains the tdTomato gene editing target and the fusion gene designed in this invention (including the gene encoding the Cas12i3 protein, the gene encoding the T5 exonuclease, and the linker gene designed in this invention). After being introduced into recipient cells, the guide RNA transcribed from it can target the tdTomato gene through base complementarity pairing. The fusion protein expressed by it (the fusion protein formed by the connection of the Cas12i3 protein and the T5 exonuclease through the linker) causes DNA double-strand breaks upstream and downstream of the tdTomato gene target. After the breaks, T5 exo can remove the protruding overhang, thereby preventing the cell from accurately repairing the DNA, increasing the insertion / deletion ratio, and further realizing the gene editing function.

[0177] 3. Flow cytometry analysis of tdTomato fluorescence changes

[0178] The plasmids (gene editing vectors pCBh-N-linker 1-gRNA2, pCBh-N-linker 2-gRNA2, pCBh-N-linker 3-gRNA2, pCBh-N-linker 4-gRNA2, pCBh-C-linker 1-gRNA2, pCBh-C-linker 2-gRNA2, pCBh-C-linker 3-gRNA2, and pCBh-C-linker 4-gRNA2) were transfected into the tdTomato red fluorescently labeled sheep fibroblasts constructed in step 1. The electroporation procedure was the same as that in Example 2. Forty-eight hours later, flow cytometry was used to analyze the effects of the control group and different nucleic acid combinations on the changes in tdTomato red fluorescence intensity in EGFP-positive cells (only EGFP-positive cells were considered because the control vector and the eight gene-editing vectors all carried the EGFP expression sequence, which originated from the PX458 vector; EGFP-positive cells represent cells successfully transfected with the plasmid, helping to reduce errors caused by cell transfection). Specifically, the proportion of tdTomato average fluorescence intensity quenched and the fluorescence intensity of cells with weaker fluorescence intensity (tdTomato fluorescence intensity less than 10 in EGFP-positive cells) were calculated. 3The percentage of cells in the group.

[0179] Calculations of the proportion of quenched average fluorescence intensity of tdTomato cells in EGFP-positive cells showed that, compared to the control group, the C-linker 3 combination modification increased the proportion of quenched average fluorescence intensity of tdTomato cells. Figure 2 This indicates that the C-linker3 combination has high editing efficiency on the tdTomato gene, resulting in the inactivation of tdTomato protein in many cells, ultimately leading to weakened or even quenched red fluorescence in many cells, thus reducing the overall cellular tdTomato fluorescence intensity; that is, the proportion of quenched average tdTomato fluorescence intensity is relatively large. Similarly, by calculating the weak tdTomato fluorescence intensity in EGFP-positive cells (<10... 3 The percentage of cells showing that, compared with the control group, the C-linker 3 combination significantly improved the fluorescence intensity of weak tdTomato (<10). 3 The percentage of cells in the cell count () Figure 3 Meanwhile, flow cytometry analysis showed that, compared to the control group, the tdTomato fluorescence peak of C-linker 3 shifted to the left overall. Figure 4 The results indicate that the C-linker3 combination has a high editing efficiency on the tdTomato gene, causing the tdTomato protein to become inactive in many cells, which ultimately leads to a decrease or even quenching of red fluorescence, resulting in a decrease in the overall tdTomato fluorescence intensity of the cell population.

[0180] This invention designs eight nucleic acid molecule combinations by fusing the T5 exonuclease to the N-terminus or C-terminus of the Cas12i3 protein using four linkers. Through T7E1 enzyme digestion experiments and flow cytometry analysis, some nucleic acid combinations (N-linker 4, C-linker 1, C-linker 3), especially the C-linker 3 combination which links T5 to the C-terminus of Cas12i3 using SGGSGGSGGS, significantly improve the editing efficiency of the Cas enzyme and has good application prospects.

[0181] The fusion protein obtained by modifying the Cas12i3 protein according to the C-linker 3 combination method is Cas12i3-SGGSGGSGGS-T5 exo. The amino acid sequence of the fusion protein Cas12i3-SGGSGGSGGS-T5 exo is SEQ ID No. 9, and its encoding gene is the Cas12i3-linker 3-T5 exo gene. The nucleotide sequence of the Cas12i3-linker 3-T5 exo gene is SEQ ID No. 10.

[0182] The fusion protein obtained by modifying the Cas12i3 protein according to the N-linker 4 combination method is T5exo-XTEN-Cas12i3. The amino acid sequence of the fusion protein T5exo-XTEN-Cas12i3 is SEQ ID No. 11, and its encoding gene is the T5exo-linker 4-Cas12i3 gene. The nucleotide sequence of the T5exo-linker 4-Cas12i3 gene is SEQ ID No. 12.

[0183] The fusion protein obtained by modifying the Cas12i3 protein according to the C-linker 1 combination method is Cas12i3-(GGGGS)2-T5 exo. The amino acid sequence of the fusion protein Cas12i3-(GGGGS)2-T5 exo is SEQ ID No. 13, and its encoding gene is the Cas12i3-linker 1-T5 exo gene. The nucleotide sequence of the Cas12i3-linker 1-T5 exo gene is SEQ ID No. 14.

[0184] The present invention has been described in detail above. For those skilled in the art, the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. Although specific embodiments have been given, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein. Some of the essential features can be applied within the scope of the following appended claims.

Claims

1. A fusion protein, characterized in that, The fusion protein is any one of the following: A1) Proteins whose amino acid sequence is SEQ ID No. 9, SEQ ID No. 11, or SEQ ID No. 13; A2) A fusion protein with the same function is obtained by attaching a tag or signal peptide to the N-terminus and / or C-terminus of A1).

2. A nucleic acid molecule, characterized in that, The nucleic acid molecule is any one of the following: B1) A nucleic acid molecule encoding the fusion protein of claim 1; B2) The coding sequence is a DNA molecule shown in SEQ ID No. 10, SEQ ID No. 12, or SEQ ID No. 14; B3) The nucleotide sequence is the DNA molecule shown in SEQ ID No. 10, SEQ ID No. 12 or SEQ ID No.

14.

3. A biomaterial, characterized in that, The biomaterial is any one of the following: C1) An expression cassette containing the nucleic acid molecule of claim 2; C2) A recombinant vector containing the nucleic acid molecule of claim 2, or a recombinant vector containing the expression cassette of C1); C3) A recombinant microorganism containing the nucleic acid molecule of claim 2, or a recombinant microorganism containing the expression cassette of C1), or a recombinant microorganism containing the recombinant vector of C2); C4) A recombinant host cell containing the nucleic acid molecule of claim 2, or a recombinant host cell containing the expression cassette of C1), or a recombinant host cell containing the recombinant vector of C2).

4. Any of the following applications of the fusion protein of claim 1, the nucleic acid molecule of claim 2, and / or the biomaterial of claim 3: Applications of D1 in gene editing; Application of D2 in the preparation of gene editing systems; Application of D3 in the preparation of gene editing products; Application of D4 in improving gene editing efficiency.

5. A gene editing system, characterized in that, The gene editing system includes any of the following: E1) The fusion protein according to claim 1; E2) The nucleic acid molecule according to claim 2; E3) The recombinant vector as described in claim 3.

6. The gene editing system according to claim 5, characterized in that, The gene editing system also includes gRNA or gRNA expression vector.

7. The application of the gene editing system according to claim 5 or 6 in gene editing, preparation of gene editing products, or improvement of gene editing efficiency.

8. A gene editing method, characterized in that, The method includes the steps of gene editing using the fusion protein of claim 1, the nucleic acid molecule of claim 2, the recombinant vector of claim 3, and / or the gene editing system of claim 5 or 6.

9. A method for improving the efficiency of Cas protein-mediated gene editing, characterized in that, The method includes any of the following: F1) The T5 exonuclease is linked to the C-terminus of the Cas protein via linker3, and the amino acid sequence of linker3 is SEQ ID No. 3; F2) The T5 exonuclease is linked to the N-terminus of the Cas protein via linker4, and the amino acid sequence of linker4 is SEQ ID No. 4; F3) The T5 exonuclease is linked to the C-terminus of the Cas protein via linker1, and the amino acid sequence of linker1 is SEQ ID No. 1; The Cas protein is the Cas12i3 protein; the amino acid sequence of the Cas12i3 protein is positions 1-1045 of SEQ ID No. 9; The amino acid sequence of the T5 exonuclease is shown in positions 1056-1346 of SEQ ID No.

9.

10. The method according to claim 9, characterized in that, The method further includes the step of constructing the nucleic acid molecule of claim 2 and the nucleic acid molecule encoding gRNA into a vector to prepare a gene editing vector.

Citation Information

Patent Citations

  • Novel CRISPR / Cas12f enzymes and systems

    CN111757889B

  • Novel CRISPR / Cas12f enzymes and systems

    CN113106081A

  • Application of 5 '-&gt; 3' exonuclease in gene editing system, gene editing system and editing method of gene editing system

    CN116286741A

  • Novel CRISPR-Cas12i system and application thereof

    CN118749029A

  • Prime editing guide RNAS, compositions thereof, and methods of using the same

    US20230357766A1